Topic
Teva
2 articles

Direct Listing
Teva Counts Its NYSE Direct Listing Among Q3 Milestones
Teva's Q3 release lists the NYSE direct listing of its ordinary shares beside an investment-grade return and $4.9 billion of refinancing. What it signals.

Direct Listing
Teva Replaces ADSs With an NYSE Direct Listing of Its Shares
Teva will swap its NYSE ADSs one-for-one for ordinary shares that start trading directly on the NYSE on September 14, 2026, with its Tel Aviv listing unchanged.